You are here

Article Text

Article menu

Download PDFPDF

General and risk management, patient safety
GRP-011 Adherence to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Free
  1. V González Rosa1,
  2. MM Viña Romero2,
  3. F Gutiérrez Nicolás3,
  4. R Gavira Moreno1,
  5. MT Moreno Carvajal1,
  6. F Gómez de Rueda1,
  7. R Gázquez Pérez1,
  8. P Gómez Germá1,
  9. A Almendral Vicente1,
  10. MT Gómez de Travecedo y Calvo1
  1. 1Hospital SAS Jerez de la Frontera, UGC-Farmacia, Jerez de la Frontera (Cádiz), Spain
  2. 2Hospital Universitario Nuestra Señora de Candelaria, UGC-Farmacia, Tenerife, Spain
  3. 3Hospital Universitario de Canarias, UGC-Farmacia, Tenerife, Spain

Abstract

Background Improved survival associated with tyrosine kinase inhibitor (TKI) treatment has transformed chronic myeloid leukaemia (CML) into a long-term disease, but therapeutic success is challenged with poor medicines adherence. Controlling side effects in combination with patient education that includes direct communication between the pharmacist and the patient are essential components for maximising the benefits of TKI treatment.

Purpose To estimate the adherence to oral chemotherapy and describe side effects with TKI treatment and their impact on adherence in patients with CML.

Materials and Methods An 18-month retrospective observational study (from January 2011 to June 2012) was made on patients diagnosed with CML in which patients were selected who collected medicines in the pharmacy and who were being treated with selected TKIs (imatinib, dasatinib, nilotinib).

The SMAQ interview was used to determinate adherence. Adherence data, side effects and demographic characteristics of the patients were tabulated using Excel. The x2 test was used for categorical variables and the t-test was used for normally-distributed continuous variables using SPSS statistical software.

Results 25 patients were included in the study. 16 were men and 9 were women. The mean age was 60 years (25–88). Imatinib was the first line treatment for all patients. The average adherence was 62.5%.

Adherence for patients younger than 50 years was 83.3% and in older patients was 55.6% (P = 0.125). Relating to years of treatment: less than 4 years 70.0% but for longer treatment 57.1% (p = 0.521). Patients with side effects showed less adherence: gastrointestinal disorders (80.0% vs. 64.28%, p = 0.402), musculoskeletal pain (70.0% vs. 42.8% p = 0.188).

Conclusions Data suggest that more than one-third of patients are poorly adherent to TKI treatment. Identifying risk factors such as side effects, and educating patients on the need to take medicines as prescribed is essential to help patients to achieve maximum benefit from their treatment.

No conflict of interest.

https://doi.org/10.1136/ejhpharm-2013-000276.011

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.